Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
FTC began the process to unionize back in 2023, raising concerns about their access to telework, potential politicization of the civil service and other issues.
Federal regulators have filed an administrative complaint against the St. Louis-based pharmacy benefit manager. Patients and ...
As the youngest ever Federal Trade Commission chair, Lina Khan has taken on scores of companies and preached the perils of business monopolies. Her pursuit of big business represents a policy ...
Amid intense focus on AI and a flurry of consumer privacy law updates, legislative activity has continued to change data breach ...
A Federal Trade Commission (FTC) report found that social and video streaming services pose serious privacy risks, especially ...
Ohio Attorney General Dave Yost and 11 other Republican attorneys general on Monday filed a brief in federal court in ...
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
The FTC launches Operation AI Comply to combat deceptive AI practices, targeting companies like DoNotPay and Ascend Ecom for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback